CL2018003537A1 - Lípidos con un número impar de átomos de carbono y su uso como una composición farmacéutica o como un suplemento nutricional. - Google Patents

Lípidos con un número impar de átomos de carbono y su uso como una composición farmacéutica o como un suplemento nutricional.

Info

Publication number
CL2018003537A1
CL2018003537A1 CL2018003537A CL2018003537A CL2018003537A1 CL 2018003537 A1 CL2018003537 A1 CL 2018003537A1 CL 2018003537 A CL2018003537 A CL 2018003537A CL 2018003537 A CL2018003537 A CL 2018003537A CL 2018003537 A1 CL2018003537 A1 CL 2018003537A1
Authority
CL
Chile
Prior art keywords
diseases
muscles
lipids
carbon atoms
nutritional supplement
Prior art date
Application number
CL2018003537A
Other languages
English (en)
Inventor
Yuhong Dong
Chun-Hsiung Chang
Shentang Lin
Original Assignee
Sunregen Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunregen Healthcare Ag filed Critical Sunregen Healthcare Ag
Publication of CL2018003537A1 publication Critical patent/CL2018003537A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A61K36/12—Filicopsida or Pteridopsida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE AL USO DE LÍPIDOS PORTADORES DE ÁCIDOS GRASOS CON UN NÚMERO IMPAR DE ÁTOMOS DE CARBONO COMO PRODUCTOS FARMACÉUTICOS O COMO UN SUPLEMENTO NUTRICIONAL. EN PARTICULAR, ESTOS LÍPIDOS SE UTILIZAN EN EL TRATAMIENTO Y/O EN LA PREVENCIÓN DE LAS ENFERMEDADES NEURO–DEGENERATIVAS, LAS ENFERMEDADES DEGENERATIVAS ÓPTICAS Y RETINALES, LAS ENFERMEDADES DESMIELINIZANTES, LOS TRASTORNOS NEURO–MUSCULARES Y DISTROFIA MUSCULAR, LA LESIÓN DE NERVIOS DEL CEREBRO O DE LA MÉDULA ESPINAL, LAS ENFERMEDADES RELACIONADAS CON AMILOIDES, OTRAS ENFERMEDADES CRÓNICAS SELECCIONADAS A PARTIR DE LAS ENFERMEDADES RENALES, DIABETES O ASMA, PERO TAMBIÉN COMO UN ALIMENTO FUNCIONAL O UN SUPLEMENTO ALIMENTICIO CONTRA EL ENVEJECIMIENTO O PARA LA PROLONGACIÓN DE LA VIDA Y PARA MEJORAR LA FUNCIÓN DEL CEREBRO PARA HUMANOS Y / O ANIMALES. MÁS AÚN, LA PRESENTE INVENCIÓN SE REFIERE A LA HIERBA OPHIOGLOSSUM, LA CUAL SE PUEDE UTILIZAR PARA EL TRATAMIENTO Y/O LA PREVENCIÓN DE ESTAS ENFERMEDADES.
CL2018003537A 2016-06-08 2018-12-07 Lípidos con un número impar de átomos de carbono y su uso como una composición farmacéutica o como un suplemento nutricional. CL2018003537A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662347103P 2016-06-08 2016-06-08

Publications (1)

Publication Number Publication Date
CL2018003537A1 true CL2018003537A1 (es) 2019-05-03

Family

ID=60577583

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003537A CL2018003537A1 (es) 2016-06-08 2018-12-07 Lípidos con un número impar de átomos de carbono y su uso como una composición farmacéutica o como un suplemento nutricional.

Country Status (13)

Country Link
US (2) US11406616B2 (es)
EP (1) EP3468551A4 (es)
JP (2) JP6872805B2 (es)
KR (1) KR20190017873A (es)
CN (2) CN110300581B (es)
AU (1) AU2017277005B2 (es)
CA (1) CA3026152A1 (es)
CL (1) CL2018003537A1 (es)
MX (1) MX2018015188A (es)
NZ (1) NZ749389A (es)
SG (1) SG11201810580PA (es)
TW (1) TWI749016B (es)
WO (1) WO2017211274A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020004023A2 (pt) * 2017-09-12 2020-09-08 Sunregen Healthcare Ag uso de um composto e composição farmacêutica ou suplemento nutricional
CN111773274A (zh) * 2019-09-20 2020-10-16 厦门医学院 瓶尔小草及车前子组合物在制备降血糖及降血压的药物组合物中的应用
CN111773351A (zh) * 2019-09-20 2020-10-16 厦门医学院 瓶尔小草及姜黄组合物在制备降血糖及降血压的药物组合物中的应用
WO2021107084A1 (ja) * 2019-11-27 2021-06-03 リファインホールディングス株式会社 インスリン分泌促進剤並びにこれを用いた血糖値改善剤、糖尿病改善剤及び食品
KR20240022560A (ko) * 2021-06-18 2024-02-20 썬리겐 헬쓰케어 아게 바이러스 감염의 신경학적 합병증의 치료 및 예방을 위한 신규 화합물
JP2023061448A (ja) * 2021-10-20 2023-05-02 リファインホールディングス株式会社 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品
WO2024075625A1 (ja) * 2022-10-02 2024-04-11 リファインホールディングス株式会社 視野欠損障害、光誘発眼組織障害およびその関連障害の予防剤、進行防止剤、改善剤、並びに食品

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS558351A (en) 1978-07-05 1980-01-21 Hitachi Ltd Press machine
DE3032300A1 (de) 1980-08-27 1982-04-01 Alfred Ing. Wien Lohninger Mittel zur parenteralen ernaehrung
JPS5919775U (ja) 1982-07-26 1984-02-06 ワイケイケイ株式会社 カ−テンウオ−ルの断熱窓
JPH02247125A (ja) 1989-03-17 1990-10-02 Koken Kk 悪性腫瘍細胞増殖抑制剤
JP3558351B2 (ja) 1992-12-07 2004-08-25 邦郎 辻 免疫抑制剤
DE19821003A1 (de) * 1998-05-11 1999-11-18 Dresden Arzneimittel Neue 1,2,5-trisubstituierte 1,2-dihydro-indazol-3-one mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DK1292294T3 (da) 2000-05-01 2009-06-22 Accera Inc Anvendelse af mediumkæde-triglycerider til behandling og forebyggelse af Alzheimers sygdom
WO2001095914A1 (en) 2000-06-14 2001-12-20 William Leslie Porter Lipids for modulating immune response
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
DE60223670T2 (de) 2001-04-18 2008-03-06 Prometic Biosciences Inc., Mont-Royal Fettsäuren als Faktoren für das Überleben und die Aktivierung von Neutrophilen.
CN1764446A (zh) * 2003-03-13 2006-04-26 康福玛医药公司 含有长链和中链甘油三酯的药物制剂
EP1628622A4 (en) 2003-05-20 2008-12-17 Baylor Res Inst FIVE AND FIFTH CARBON FATTY ACIDS FOR THE TREATMENT OF METABOLISM DISORDERS AND AS FOOD SUPPLEMENTS
JP4334956B2 (ja) * 2003-09-18 2009-09-30 株式会社ノエビア 細胞賦活剤、美白剤、及び抗酸化剤
CN101137369A (zh) * 2005-02-09 2008-03-05 马库赛特公司 用于眼治疗的制剂
NZ575655A (en) 2006-09-26 2012-06-29 Baylor Res Inst Nutrient sensor
EP1929995A1 (en) 2006-12-04 2008-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anaplerotic therapy of Huntington disease and other polyglutamine diseases
KR100829729B1 (ko) * 2007-01-29 2008-05-15 한불화장품주식회사 병이소초 추출물을 주요 활성성분으로 함유하는 피부외용제 조성물
CN101878028A (zh) 2007-11-02 2010-11-03 普罗米蒂克生物科学公司 作为肾保护剂的中链长度脂肪酸和甘油酯
DE102008046227A1 (de) * 2008-06-10 2009-12-17 Ludwig-Maximilians-Universität München Hochdurchsatzmethode zur Analyse der Fettsäurezusammensetzung in Plasmaphosphoglyceriden
DE102008057867A1 (de) 2008-11-18 2010-05-20 B. Braun Melsungen Ag Fettemulsion zur künstlichen Ernährung von schwerkranken Intensivpatienten
CN101879156B (zh) 2009-05-07 2013-01-30 上海医药工业研究院 一种药物组合物及其应用
AU2010336921A1 (en) 2009-12-30 2012-07-26 Baylor Research Institute Anaplerotic therapy for Alzheimer's disease and the aging brain
SG182414A1 (en) * 2010-01-08 2012-08-30 Catabasis Pharmaceuticals Inc Fatty acid fumarate derivatives and their uses
WO2011099570A1 (ja) * 2010-02-10 2011-08-18 オリザ油化株式会社 Ａｇｅ産生抑制剤
US20110301238A1 (en) * 2010-06-02 2011-12-08 Borges Karin Seizure related disorders and therapeutic methods thereof
KR20130041902A (ko) 2010-06-14 2013-04-25 베일러 리서치 인스티튜트 성인 폴리글루코산체병（ａｐｂｄ）의 치료를 위한 트리헵타노인 식이
AU2011278352B2 (en) * 2010-07-15 2016-07-21 Hybrigenics Sa Formulations of 14 - epi -analogues of vitamin D
CN107028926A (zh) 2011-08-26 2017-08-11 国立大学法人大阪大学 糖尿病性心血管并发症的预防/治疗剂
CN102526643B (zh) * 2012-03-22 2013-09-11 常熟市虞山绿茶有限公司 一种治疗口腔溃疡的中草药含片
BR112015013349A2 (pt) 2012-12-13 2017-07-11 Baylor Res Institute At Dallas trieptanoína para o tratamento de deficiência de transportador de glicose 1
ES2806701T3 (es) * 2013-08-02 2021-02-18 Swm Luxembourg Sarl Producto comestible que comprende material vegetal reconstituido
ES2774321T3 (es) * 2013-11-14 2020-07-20 Univ Queensland Trastornos neurodegenerativos y métodos de tratamiento y diagnóstico de los mismos
CN103641713B (zh) * 2013-11-15 2015-10-21 浙江大学 甘油单酯衍生物的制备方法及应用
WO2015110977A1 (en) 2014-01-22 2015-07-30 Rolexi Marketing (Pty) Ltd Fatty acid composition and medicinal use thereof
CN104286296A (zh) * 2014-09-25 2015-01-21 王美华 一种凉茶
JP6406978B2 (ja) 2014-11-04 2018-10-17 株式会社シー・アクト 脂肪酸混合物
CN105267501A (zh) * 2015-11-04 2016-01-27 夏茂森 一种治疗毒蛇咬伤的中药组合物
CN105381182A (zh) 2015-11-20 2016-03-09 冯天寿 一种治疗慢性荨麻疹的中药及其应用
CN108289873A (zh) 2015-12-04 2018-07-17 雀巢产品技术援助有限公司 用于改善认知的方法

Also Published As

Publication number Publication date
EP3468551A1 (en) 2019-04-17
TW201801720A (zh) 2018-01-16
CN110300581A (zh) 2019-10-01
JP2021113204A (ja) 2021-08-05
JP2019518034A (ja) 2019-06-27
AU2017277005A1 (en) 2019-01-17
MX2018015188A (es) 2019-08-21
US20190255129A1 (en) 2019-08-22
NZ749389A (en) 2022-12-23
CN110300581B (zh) 2023-09-08
SG11201810580PA (en) 2018-12-28
CN117298092A (zh) 2023-12-29
US20220362197A1 (en) 2022-11-17
WO2017211274A1 (en) 2017-12-14
AU2017277005B2 (en) 2022-12-22
KR20190017873A (ko) 2019-02-20
TWI749016B (zh) 2021-12-11
EP3468551A4 (en) 2020-01-22
US11406616B2 (en) 2022-08-09
JP6872805B2 (ja) 2021-05-19
CA3026152A1 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
CL2018003537A1 (es) Lípidos con un número impar de átomos de carbono y su uso como una composición farmacéutica o como un suplemento nutricional.
CY1120663T1 (el) Dpa-εμπλουτισμενες συνθεσεις ωμεγα-3 πολυακορεστων λιπαρων οξεων σε μορφη ελευθερου οξεος
PE20151771A1 (es) Composiciones nutricionales que contienen un componente neurologico y los usos del mismo
AR097110A1 (es) Composiciones nutricionales que contienen una combinación sinérgica y usos de las mismas
EA202090948A1 (ru) Иммуномодуляция
BR112015027281A8 (pt) usos de uma população de nanocarreadores sintéticos que são fixados a imunossupressores e composição compreendendo a referida população de nanocarreadores
EA201070419A1 (ru) Состав для регулирования метаболизма липидов
BR112014001907A2 (pt) produção de dha e outros lc-pufas em plantas
AR104835A1 (es) Composiciones nutricionales que contienen un nivel elevado de inositol y uso de las mismas
WO2014140873A3 (en) Omega- 3 phospholipid supplements for improved brain maturity
PH12018500036A1 (en) Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid
EP2560633A4 (en) INTRAVENOUS COMPOSITIONS OF OMEGA-3 FATTY ACIDS AND METHOD OF USE
PH12018500035A1 (en) Nutritional compositions and methods for promoting cognitive development
NZ747847A (en) Lipid compositions
CO2019012475A2 (es) Composiciones y productos de fragancia novedosos con efectos mejoradores del estado de ánimo
CY1123942T1 (el) Συνθεσεις ωμεγα-3 λιπαρων οξεων για τη θεραπεια ασθενειων που επιφερουν βλαβη στο νευρικο συστημα
CR20140473A (es) Compuestos de pirazol como inhibidores de sglt1
CO2017005911A2 (es) Método para incrementar niveles de ácidos grasos de omega-3 en productos de carne de res por medio de administración de una dieta de pasto y algas
ES2664518T3 (es) Producto alimenticio saludable que contiene ésteres etílicos de ácidos grasos de aceite de linaza, y procedimiento de obtención del mismo
PH12020500511A1 (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
MX2016013680A (es) Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos.
GT201400115A (es) Combinación farmacéutica antineurítica y composición
AR110542A1 (es) Composiciones nutricionales que contienen inositol y usos de las mismas
PL408304A1 (pl) Zastosowanie preparatu fosfolipidowego z żółtek jaj
TH178071A (th) องค์ประกอบทางโภชนาการที่มีส่วนแยกที่ถูกทำให้มีไลปิดมากขึ้นและการใช้ของมัน